TOKYO – An ongoing downturn in global trade may turn out to be unexpectedly severe, but in the midst of the ongoing difficulties there may be opportunities for biotech companies. That was the opinion of industry executives speaking at the Bio Asia International Conference last week, as they generally agreed that this year should be a good one for biotech stocks, in no small part thanks to an expected recovery from the sharp correction during the last quarter of 2018.